California State Teachers Retirement System Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

California State Teachers Retirement System reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 0.1% during the third quarter, Holdings Channel reports. The firm owned 179,870 shares of the biopharmaceutical company’s stock after selling 250 shares during the quarter. California State Teachers Retirement System’s holdings in Regeneron Pharmaceuticals were worth $123,907,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. FMR LLC increased its position in Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. FMR LLC now owns 10,176,199 shares of the biopharmaceutical company’s stock valued at $6,015,457,000 after purchasing an additional 193,175 shares during the period. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 8,648,125 shares of the biopharmaceutical company’s stock valued at $5,957,433,000 after purchasing an additional 77,380 shares during the period. Dodge & Cox increased its position in Regeneron Pharmaceuticals by 1.3% during the 2nd quarter. Dodge & Cox now owns 2,265,334 shares of the biopharmaceutical company’s stock valued at $1,339,107,000 after purchasing an additional 28,271 shares during the period. Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 1,750,561 shares of the biopharmaceutical company’s stock valued at $1,205,910,000 after purchasing an additional 56,253 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Regeneron Pharmaceuticals by 6.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,022,724 shares of the biopharmaceutical company’s stock worth $704,526,000 after buying an additional 64,867 shares during the period. 84.25% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider George Yancopoulos sold 13,189 shares of the company’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $800.08, for a total transaction of $10,552,255.12. Following the transaction, the insider now owns 200,504 shares in the company, valued at approximately $160,419,240.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider George Yancopoulos sold 13,189 shares of the company’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $800.08, for a total transaction of $10,552,255.12. Following the completion of the sale, the insider now owns 200,504 shares of the company’s stock, valued at approximately $160,419,240.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director N Anthony Coles sold 5,758 shares of the company’s stock in a transaction dated Wednesday, December 28th. The shares were sold at an average price of $714.11, for a total transaction of $4,111,845.38. Following the sale, the director now directly owns 1,093 shares of the company’s stock, valued at approximately $780,522.23. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,273 shares of company stock worth $21,189,979. Company insiders own 8.99% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Cowen raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $775.00 to $875.00 in a research report on Monday, January 30th. Royal Bank of Canada upped their target price on shares of Regeneron Pharmaceuticals from $787.00 to $806.00 and gave the stock a “sector perform” rating in a research report on Thursday, March 9th. StockNews.com assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday. They issued a “buy” rating on the stock. JPMorgan Chase & Co. raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 target price on the stock in a research report on Friday, January 20th. Finally, Cowen raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $775.00 to $875.00 in a research report on Monday, January 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $815.38.

Regeneron Pharmaceuticals Price Performance

REGN opened at $760.30 on Thursday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.29 and a current ratio of 5.06. The stock has a market capitalization of $83.12 billion, a P/E ratio of 19.88, a P/E/G ratio of 2.57 and a beta of 0.21. The company’s 50-day simple moving average is $745.90 and its two-hundred day simple moving average is $727.42. Regeneron Pharmaceuticals, Inc. has a 52-week low of $538.01 and a 52-week high of $800.48.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last posted its earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.18 by $4.38. The business had revenue of $3.41 billion for the quarter, compared to analysts’ expectations of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The business’s revenue for the quarter was down 31.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $23.72 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 34.22 EPS for the current year.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.